Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis | Zendy

Edward Thomsen | Zendy; Nelly Sanuku | Zendy; Manasseh Baea | Zendy; Samson Satofan | Zendy; Elit Maki | Zendy; Bart Lombore | Zendy; Mark S. Schmidt | Zendy; Peter M. Siba | Zendy; Gary J. Weil | Zendy; James W. Kazura | Zendy; Lawrence Fleckenstein | Zendy; Christopher L. King | Zendy

Open Access

Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis

Author(s) -

Edward Thomsen,

Nelly Sanuku,

Manasseh Baea,

Samson Satofan,

Elit Maki,

Bart Lombore,

Mark S. Schmidt,

Peter M. Siba,

Gary J. Weil,

James W. Kazura,

Lawrence Fleckenstein,

Christopher L. King

Publication year - 2015

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/civ882

Subject(s) - diethylcarbamazine , microfilaria , medicine , wuchereria bancrofti , lymphatic filariasis , albendazole , ivermectin , anthelmintic , pharmacokinetics , regimen , gastroenterology , filariasis , pharmacology , surgery , immunology , veterinary medicine , helminths

Available treatments for lymphatic filariasis (LF) are limited in their longterm clearance of microfilaria from the blood. The safety and efficacy of a single-dose triple-drug therapy of the antifilarial drugs diethylcarbamazine (DEC), ivermectin (IVM), and albendazole (ALB) for LF are unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research